NCT05357313Active, not recruiting
Adjunctive Bright Light Therapy in Patients With Bipolar Depression and Eveningness
A Randomized Placebo-controlled Trial for Adjunctive Bright Light Therapy in Patients With Bipolar Depression and Eveningness
Source: ClinicalTrials.gov · Last updated 5 Mar 2026
Brief summary (registry, in English)
This is a randomized placebo-controlled trial to examine the efficacy of six-week bright light therapy as adjunctive treatment for patient with bipolar depression and eveningness.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 70 (estimated)
- First submitted
- 27 Apr 2022
- Start date
- 2 Jun 2022
- Primary completion date
- 28 Nov 2025
- Lead sponsor
- Chinese University of Hong Kong
- Diseases
- Bipolar disorder
- NCT number
- NCT05357313
What you commit to
- Study type: Interventional
- Planned participants: 70
- From 2 Jun 2022 to the primary completion date, 28 Nov 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Receiving regular psychotherapy.
Other illness
- Major Depressive Disorder fulfilling the Seasonal Pattern Specifier of the DSM-V (Seasonal Affective Disorder).
- A past history of rapid-cycling within the past twelve months or a Young Mania Rating Scale more than 12 at screening
- A current or past history of schizophrenia, mental retardation, organic mental disorder; or current substance use disorder.
- Presence of contraindications to bright light therapy: for example, history of light induced migraine/ epilepsy; current use of photosensitizing medications such as St. John's wart; presence of eye disease: e.g. retinal blindness, severe cataract, glaucoma, and photosensitive skin condition e.g. systemic lupus erythematosus
- Significant medical condition/ hearing impairment/ speech deficit leading to incapability of completing clinical interview.
Other
- Presence of psychotic symptoms or substantial suicidal risk as judged by the clinician and/or screening instruments.
- Regular shift-workers or trans-meridian flight in the past 3 months or during study
- Enrolment in another clinical trial of an investigational medicinal product or device.
Who the study is looking for
- Aged 18-65 years.
- Is capable to give informed consent.
- Meeting the diagnostic criteria of bipolar depression (including both bipolar I and II disorders) by the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-V), Disorders (SCID-V).
- a score 20 or above representing current moderate or severe episode of major depression and a score of at least 1 on items H1 or H2 on the Structured Interview Guide for the Hamilton Depression Rating Scale with Atypical Depression Supplement (SIGH-ADS), corresponding to at least moderate severity.
- A score of 41 or less by the Morningness-Eveningness Questionnaire which represents eveningness.
- On a stable dose of antimanic treatment for bipolar disorder for at least four weeks.
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The Chinese University of Hong Kong Coordinator of this site? Confirm its status | Hong Kong | Hong Kong SAR China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.